Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Integra Lifesciences Holdings OCF Yield %?
Integra Lifesciences HoldingsSTU:IL3 +2.50%74 OCF Yield % is 4.89 as of Jul. 16, 2026, which is 4% below its 10-year median of 5.12. GuruFocus rates STU:IL3 with a GF Score™ of 74/100 and a GF Value™ of €20.79 (Modestly Undervalued). The stock has 11 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Integra Lifesciences Holdings ranks better than 66.08% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Integra Lifesciences Holdings's OCF Yield % or its related term are showing as below:
STU:IL3'
s OCF Yield % Range Over the Past 10 Years
Min: 2.37 Med: 5.12 Max: 11.54
Current: 4.89
During the past 13 years, the highest OCF Yield % of Integra Lifesciences Holdings was 11.54%. The lowest was 2.37%. And the median was 5.12%.
STU:IL3's OCF Yield % is ranked better than 66.08% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 1.69
vs STU:IL3: 4.89
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Integra Lifesciences Holdings OCF Yield % Related Terms
Integra Lifesciences Holdings OCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:IL3 vs ATEC, AHCO, INSP: OCF Yield % Comparison
For the Medical Devices subindustry, Integra Lifesciences Holdings's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integra Lifesciences Holdings OCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Integra Lifesciences Holdings's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Integra Lifesciences Holdings's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integra Lifesciences Holdings (STU:IL3) has a OCF Yield % of 4.89 as of Jul. 16, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Integra Lifesciences Holdings and its competitors. This is near median its historical median of 5.12. Over the past decade, Integra Lifesciences Holdings' OCF Yield % has ranged from 2.37 to 11.54. According to the industry distribution chart, Integra Lifesciences Holdings ranks #289 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 33.9%.
Is Integra Lifesciences Holdings' OCF Yield % too high?
Integra Lifesciences Holdings' current OCF Yield % of 4.89 is near median its 10-year median of 5.12. Over the past 10 years, this metric has ranged from a low of 2.37 to a high of 11.54. The Medical Devices & Instruments industry median OCF Yield % is 1.69. Integra Lifesciences Holdings' value of 4.89 is 189.3% above this industry median. Based on the distribution chart, Integra Lifesciences Holdings ranks #289 out of 852 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Integra Lifesciences Holdings has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integra Lifesciences Holdings' OCF Yield % compare to ATEC and AHCO?
According to the Medical Devices & Instruments industry distribution chart, Integra Lifesciences Holdings ranks #289 out of 852 companies for OCF Yield %. This puts Integra Lifesciences Holdings in the upper half of its industry. The industry median OCF Yield % is 1.69. Integra Lifesciences Holdings' value of 4.89 is 189.3% above this benchmark. Historically, Integra Lifesciences Holdings' own OCF Yield % has ranged from 2.37 to 11.54 over the past decade. While the company's 10-year median is 5.12 vs. the industry median of 1.69, Integra Lifesciences Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Devices & Instruments company?
The median OCF Yield % among Medical Devices & Instruments companies is 1.69, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integra Lifesciences Holdings's current OCF Yield % of 4.89 is 189.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Integra Lifesciences Holdings and its competitors. For the Medical Devices & Instruments industry, the median OCF Yield % is 1.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integra Lifesciences Holdings's current OCF Yield % is 4.89, which is near median its own 10-year median of 5.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integra Lifesciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integra Lifesciences Holdings (STU:IL3) is currently considered Modestly Undervalued. The stock's GF Value™ is €20.79, compared to a current price of €16.40 — trading 21.1% below its estimated fair value. The current OCF Yield % is 4.89, which is near median its 10-year median of 5.12 and 189.3% above the Medical Devices & Instruments industry median of 1.69. Integra Lifesciences Holdings' overall GF Score™ is 74/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Integra Lifesciences Holdings (STU:IL3), the current OCF Yield % is 4.89 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integra Lifesciences Holdings (STU:IL3) Overvalued in 2026?
Based on GuruFocus' analysis, Integra Lifesciences Holdings stock appears to be undervalued.
The current stock price of €16.40 is trading 21.1% below its estimated GF Value™ of €20.79.
GuruFocus considers Integra Lifesciences Holdings to be Modestly Undervalued.
Key valuation signals for STU:IL3:
OCF Yield %: 4.89 (near median its 10-year median of 5.12)
GF Value™: €20.79 vs. price of €16.40 (21.1% below fair value)
Industry Position: 189.3% above the Medical Devices & Instruments median (#289 of 852)
No single metric tells the full story. See the STU:IL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integra Lifesciences Holdings Business Description
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
74GF Score
Get the complete analysis for STU:IL3
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:IL3 has been successfully added to your 
